{"id":62181,"date":"2025-11-11T04:03:23","date_gmt":"2025-11-11T03:03:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/"},"modified":"2025-11-11T04:03:23","modified_gmt":"2025-11-11T03:03:23","slug":"samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/","title":{"rendered":"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms"},"content":{"rendered":"
\n

INCHEON, Korea–(BUSINESS WIRE)–#EpisNexLab<\/a>–Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nEpis NexLab will focus on transforming highly scalable core technologies into platforms for the discovery of diverse new drug candidates, including license-out or joint development with global pharmaceutical companies. As part of its search for new business opportunities, the company plans to explore various new modalities including amino acid or peptide conjugate platform technologies.<\/p>\n

\nPeter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to his current role as the Executive Vice President and Head of Research and Early Development at Samsung Bioepis. He will also serve on the board of directors of Samsung Epis Holdings as a non-executive director.<\/p>\n

\n\u201cBuilding on the R&D expertise accumulated through years of developing quality-assured biologics at Samsung Bioepis, we will focus on securing next-generation biotechnology platforms that can drive sustainable growth for the new company beyond the biosimilar business,\u201d said Peter Seongwon Hong, CEO of Epis NexLab. \u201cOur long-term goal is to become a leading biotechnology company in next-generation therapeutic technologies and we will be relentless in our efforts to drive this growth, through innovative research and development and strategic investment.\u201d<\/p>\n

\nEpis NexLab<\/b><\/p>\n

\nEstablished in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab will focus on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Samsung Epis Holdings and Epis NexLab, please visit: www.samsungepisholdings.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nMEDIA CONTACT \u2013 Samsung Bioepis<\/b>
Anna Nayun Kim, nayun86.kim@samsung.com<\/a>
Yoon Kim, yoon1.kim@samsung.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

INCHEON, Korea–(BUSINESS WIRE)–#EpisNexLab–Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexLab will focus on transforming highly scalable core technologies into platforms for the discovery of diverse new drug candidates, including license-out or joint development with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62181","6":"format-standard","7":"category-industry"},"yoast_head":"\nSamsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"INCHEON, Korea–(BUSINESS WIRE)–#EpisNexLab–Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexLab will focus on transforming highly scalable core technologies into platforms for the discovery of diverse new drug candidates, including license-out or joint development with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T03:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251110979915\/en\/2636624\/22\/NexLab_CEO_Peter_Seongwon_Hong.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms\",\"datePublished\":\"2025-11-11T03:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/\"},\"wordCount\":326,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110979915\\\/en\\\/2636624\\\/22\\\/NexLab_CEO_Peter_Seongwon_Hong.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/\",\"name\":\"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110979915\\\/en\\\/2636624\\\/22\\\/NexLab_CEO_Peter_Seongwon_Hong.jpg\",\"datePublished\":\"2025-11-11T03:03:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110979915\\\/en\\\/2636624\\\/22\\\/NexLab_CEO_Peter_Seongwon_Hong.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251110979915\\\/en\\\/2636624\\\/22\\\/NexLab_CEO_Peter_Seongwon_Hong.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/","og_locale":"en_US","og_type":"article","og_title":"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms - Pharma Trend","og_description":"INCHEON, Korea–(BUSINESS WIRE)–#EpisNexLab–Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexLab will focus on transforming highly scalable core technologies into platforms for the discovery of diverse new drug candidates, including license-out or joint development with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-11T03:03:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251110979915\/en\/2636624\/22\/NexLab_CEO_Peter_Seongwon_Hong.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms","datePublished":"2025-11-11T03:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/"},"wordCount":326,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251110979915\/en\/2636624\/22\/NexLab_CEO_Peter_Seongwon_Hong.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/","url":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/","name":"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251110979915\/en\/2636624\/22\/NexLab_CEO_Peter_Seongwon_Hong.jpg","datePublished":"2025-11-11T03:03:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251110979915\/en\/2636624\/22\/NexLab_CEO_Peter_Seongwon_Hong.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251110979915\/en\/2636624\/22\/NexLab_CEO_Peter_Seongwon_Hong.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-announces-establishment-of-epis-nexlab-a-new-subsidiary-to-advance-next-generation-biotechnology-platforms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62181"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62181\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}